JP7199737B2 - ピリジルピリドン化合物 - Google Patents
ピリジルピリドン化合物 Download PDFInfo
- Publication number
- JP7199737B2 JP7199737B2 JP2020510096A JP2020510096A JP7199737B2 JP 7199737 B2 JP7199737 B2 JP 7199737B2 JP 2020510096 A JP2020510096 A JP 2020510096A JP 2020510096 A JP2020510096 A JP 2020510096A JP 7199737 B2 JP7199737 B2 JP 7199737B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridyl
- pyridin
- oxo
- trifluoromethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 145
- 239000000203 mixture Substances 0.000 claims description 107
- -1 C 1 -C 3 alkoxy Chemical group 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 49
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 18
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- WEUPTDZSLQUHHB-UHFFFAOYSA-N 4-(2-aminopyridin-4-yl)-6-(2-chlorophenyl)-1H-pyridin-2-one Chemical compound NC1=NC=CC(=C1)C1=CC(NC(=C1)C1=C(C=CC=C1)Cl)=O WEUPTDZSLQUHHB-UHFFFAOYSA-N 0.000 claims description 7
- LRUDZBBEMDATJL-UHFFFAOYSA-N 4-(2-aminopyridin-4-yl)-6-pyridin-3-yl-1H-pyridin-2-one Chemical compound NC1=NC=CC(=C1)C1=CC(NC(=C1)C=1C=NC=CC=1)=O LRUDZBBEMDATJL-UHFFFAOYSA-N 0.000 claims description 7
- ULRZATBBRNFUII-UHFFFAOYSA-N N-[4-[2-(2-chlorophenyl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]-2-methoxyacetamide Chemical compound ClC1=C(C=CC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(COC)=O)=O ULRZATBBRNFUII-UHFFFAOYSA-N 0.000 claims description 7
- KYABMOVZHRXKDQ-UHFFFAOYSA-N N-[4-[2-(3-cyclopropylmorpholin-4-yl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C1(CC1)C1N(CCOC1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O KYABMOVZHRXKDQ-UHFFFAOYSA-N 0.000 claims description 7
- JTUBLRKWQWLDGI-UHFFFAOYSA-N N-[4-[2-(4-methylpyridin-3-yl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound CC1=C(C=NC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O JTUBLRKWQWLDGI-UHFFFAOYSA-N 0.000 claims description 7
- WHWGYPKJDYJZPK-UHFFFAOYSA-N N-[4-[2-[1-ethyl-3-(trifluoromethyl)pyrazol-4-yl]-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)N1N=C(C(=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O)C(F)(F)F WHWGYPKJDYJZPK-UHFFFAOYSA-N 0.000 claims description 7
- ZKBIQNBVDMYXCG-UHFFFAOYSA-N N-[4-[2-[4-ethylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)S(=O)(=O)N1CC(N(CC1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O)C(F)(F)F ZKBIQNBVDMYXCG-UHFFFAOYSA-N 0.000 claims description 7
- WYKJXFMXVUDREO-UHFFFAOYSA-N N-[4-[2-oxo-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C1=C(C=CC=C1)C(F)(F)F WYKJXFMXVUDREO-UHFFFAOYSA-N 0.000 claims description 7
- WSZRNKMWOZHSEK-UHFFFAOYSA-N N-[4-[2-oxo-6-[2-(trifluoromethyl)piperidin-1-yl]-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)N1C(CCCC1)C(F)(F)F WSZRNKMWOZHSEK-UHFFFAOYSA-N 0.000 claims description 7
- SXTBJUQDFNIUBC-UHFFFAOYSA-N N-[4-[2-oxo-6-[2-(trifluoromethyl)piperidin-1-yl]-1H-pyridin-4-yl]pyridin-2-yl]cyclopropanecarboxamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(=O)C1CC1)N1C(CCCC1)C(F)(F)F SXTBJUQDFNIUBC-UHFFFAOYSA-N 0.000 claims description 7
- FMUDKKVYHUYDHN-UHFFFAOYSA-N N-[4-[2-oxo-6-[2-(trifluoromethyl)pyridin-3-yl]-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C=1C(=NC=CC=1)C(F)(F)F FMUDKKVYHUYDHN-UHFFFAOYSA-N 0.000 claims description 7
- MVNXIWSZHATYNO-UHFFFAOYSA-N N-[4-[2-oxo-6-[3-(trifluoromethyl)morpholin-4-yl]-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)N1C(COCC1)C(F)(F)F MVNXIWSZHATYNO-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- DQKMSARXLJYZJQ-UHFFFAOYSA-N methyl N-[4-[2-(2-chlorophenyl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound ClC1=C(C=CC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(OC)=O)=O DQKMSARXLJYZJQ-UHFFFAOYSA-N 0.000 claims description 7
- HQUNJFIESNSZTF-UHFFFAOYSA-N methyl N-[4-[2-[1-ethyl-3-(trifluoromethyl)pyrazol-4-yl]-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C(C)N1N=C(C(=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(OC)=O)=O)C(F)(F)F HQUNJFIESNSZTF-UHFFFAOYSA-N 0.000 claims description 7
- BFXQCYNFXBAUJV-UHFFFAOYSA-N methyl N-[4-[2-oxo-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(OC)=O)C1=C(C=CC=C1)C(F)(F)F BFXQCYNFXBAUJV-UHFFFAOYSA-N 0.000 claims description 7
- YEHAXKAYTZMYNC-UHFFFAOYSA-N methyl N-[4-[2-oxo-6-[2-(trifluoromethyl)piperidin-1-yl]-1H-pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(OC)=O)N1C(CCCC1)C(F)(F)F YEHAXKAYTZMYNC-UHFFFAOYSA-N 0.000 claims description 7
- UYCPAINACUBWSG-UHFFFAOYSA-N methyl N-[4-[2-oxo-6-[2-(trifluoromethyl)pyridin-3-yl]-1H-pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(OC)=O)C=1C(=NC=CC=1)C(F)(F)F UYCPAINACUBWSG-UHFFFAOYSA-N 0.000 claims description 7
- JPDYKOOKVQBXPO-UHFFFAOYSA-N methyl N-[4-[2-oxo-6-[3-(trifluoromethyl)morpholin-4-yl]-1H-pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(OC)=O)N1C(COCC1)C(F)(F)F JPDYKOOKVQBXPO-UHFFFAOYSA-N 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- GRXPRRPKOQULJV-UHFFFAOYSA-N N-[4-[2-(2-chlorophenyl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound ClC1=C(C=CC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O GRXPRRPKOQULJV-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- ONHSGOPTCOTAQD-UHFFFAOYSA-N 1,1-dimethyl-3-[4-[2-oxo-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-4-yl]pyridin-2-yl]urea Chemical compound CN(C(=O)NC1=NC=CC(=C1)C1=CC(NC(=C1)C1=C(C=CC=C1)C(F)(F)F)=O)C ONHSGOPTCOTAQD-UHFFFAOYSA-N 0.000 claims description 3
- ULUDICOQHXTMDW-UHFFFAOYSA-N 3-[4-[2-(2-chlorophenyl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]-1,1-dimethylurea Chemical compound ClC1=C(C=CC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(N(C)C)=O)=O ULUDICOQHXTMDW-UHFFFAOYSA-N 0.000 claims description 3
- WGFAFMAQISHQSM-UHFFFAOYSA-N N-[4-[2-(2-chlorophenyl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound ClC1=C(C=CC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(=O)N1CCCC1)=O WGFAFMAQISHQSM-UHFFFAOYSA-N 0.000 claims description 3
- GWHGMPUKIGJYGA-UHFFFAOYSA-N N-[4-[2-(2-methylpyridin-3-yl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound CC1=NC=CC=C1C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O GWHGMPUKIGJYGA-UHFFFAOYSA-N 0.000 claims description 3
- WMNIDEIOBLFDHX-UHFFFAOYSA-N N-[4-[2-[2-(2-methoxypropan-2-yl)pyrrolidin-1-yl]-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound COC(C)(C)C1N(CCC1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O WMNIDEIOBLFDHX-UHFFFAOYSA-N 0.000 claims description 3
- DEGTWMWMGZJAKR-UHFFFAOYSA-N N-[4-[2-oxo-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-4-yl]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(=O)N1CCCC1)C1=C(C=CC=C1)C(F)(F)F DEGTWMWMGZJAKR-UHFFFAOYSA-N 0.000 claims description 3
- YHZOOIVUJYXALU-UHFFFAOYSA-N N-[4-[2-oxo-6-[4-(trifluoromethyl)thiophen-3-yl]-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C1=CSC=C1C(F)(F)F YHZOOIVUJYXALU-UHFFFAOYSA-N 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
- VTHFNINSBJBGAK-UHFFFAOYSA-N methyl N-[4-[2-(3-cyclopropylmorpholin-4-yl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C1(CC1)C1N(CCOC1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(OC)=O)=O VTHFNINSBJBGAK-UHFFFAOYSA-N 0.000 claims description 3
- ORFKZCSDPUROQG-UHFFFAOYSA-N methyl N-[4-[2-(4-methylpyridin-3-yl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound CC1=C(C=NC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(OC)=O)=O ORFKZCSDPUROQG-UHFFFAOYSA-N 0.000 claims description 3
- OZQPAJQHGQVQDC-UHFFFAOYSA-N methyl N-[4-[2-[4-ethylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C(C)S(=O)(=O)N1CC(N(CC1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(OC)=O)=O)C(F)(F)F OZQPAJQHGQVQDC-UHFFFAOYSA-N 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000004766 (C3-C6) cyclohaloalkyl group Chemical group 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 239000003667 hormone antagonist Substances 0.000 claims description 2
- 239000000367 immunologic factor Substances 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 201000003733 ovarian melanoma Diseases 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 70
- 239000012265 solid product Substances 0.000 description 51
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 235000019439 ethyl acetate Nutrition 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 239000012044 organic layer Substances 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 16
- 101150003085 Pdcl gene Proteins 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 12
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 12
- 239000012267 brine Substances 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- 230000004900 autophagic degradation Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 150000002430 hydrocarbons Chemical group 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 229930195734 saturated hydrocarbon Natural products 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- FRONOVIWVBGNCB-UHFFFAOYSA-N methyl N-[4-[2-chloro-6-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(OC)=O)Cl FRONOVIWVBGNCB-UHFFFAOYSA-N 0.000 description 5
- 150000003905 phosphatidylinositols Chemical class 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 5
- QPWQKQNKRKXWCK-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-[2-(trifluoromethyl)piperidin-1-yl]pyridine Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)B1OC(C(O1)(C)C)(C)C)N1C(CCCC1)C(F)(F)F QPWQKQNKRKXWCK-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- XXQFNTNEJRRUFX-UHFFFAOYSA-N N-[4-[2-chloro-6-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)Cl XXQFNTNEJRRUFX-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical class COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 4
- CWNIPRVRMAXJCO-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]-4-phenylmethoxy-6-[2-(trifluoromethyl)piperidin-1-yl]pyridine Chemical compound C(C1=CC=CC=C1)OC1=CC(=NC(=C1)N1C(CCCC1)C(F)(F)F)OC(C)(C)C CWNIPRVRMAXJCO-UHFFFAOYSA-N 0.000 description 3
- ZTLRFJODULZNEQ-UHFFFAOYSA-N 2-chloro-6-[(2-methylpropan-2-yl)oxy]-4-phenylmethoxypyridine Chemical compound C(C1=CC=CC=C1)OC1=CC(=NC(=C1)Cl)OC(C)(C)C ZTLRFJODULZNEQ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- RWKHOCBPUSCGAW-UHFFFAOYSA-N [2-(trifluoromethyl)pyridin-3-yl]boronic acid Chemical compound OB(O)C1=CC=CN=C1C(F)(F)F RWKHOCBPUSCGAW-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 229960004217 benzyl alcohol Drugs 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- LXSZMGQQXZXQKX-UHFFFAOYSA-N n-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]acetamide Chemical compound C1=NC(NC(=O)C)=CC(B2OC(C)(C)C(C)(C)O2)=C1 LXSZMGQQXZXQKX-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229910052717 sulfur Chemical group 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- TTYBHYJCFNWBEI-UHFFFAOYSA-N 1-ethylsulfonyl-3-(trifluoromethyl)piperazine Chemical compound C(C)S(=O)(=O)N1CC(NCC1)C(F)(F)F TTYBHYJCFNWBEI-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- WBJNURZDWBKQQF-UHFFFAOYSA-N 2,4-dichloro-6-(2-chlorophenyl)pyridine Chemical compound ClC1=NC(=CC(=C1)Cl)C1=C(C=CC=C1)Cl WBJNURZDWBKQQF-UHFFFAOYSA-N 0.000 description 2
- NGSKFMPSBUAUNE-UHFFFAOYSA-N 2,6-dichloro-4-iodopyridine Chemical compound ClC1=CC(I)=CC(Cl)=N1 NGSKFMPSBUAUNE-UHFFFAOYSA-N 0.000 description 2
- ZQQFOHVNHOYXQN-UHFFFAOYSA-N 2,6-dichloro-4-phenylmethoxypyridine Chemical compound ClC1=NC(Cl)=CC(OCC=2C=CC=CC=2)=C1 ZQQFOHVNHOYXQN-UHFFFAOYSA-N 0.000 description 2
- NAXDEFXCCITWEU-UHFFFAOYSA-N 2-(trifluoromethyl)piperidine Chemical compound FC(F)(F)C1CCCCN1 NAXDEFXCCITWEU-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- YEKZXKVUBUHSTI-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-[2-(trifluoromethyl)phenyl]pyridine Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)B1OC(C(O1)(C)C)(C)C)C1=C(C=CC=C1)C(F)(F)F YEKZXKVUBUHSTI-UHFFFAOYSA-N 0.000 description 2
- ZDEHFOOMMKTWNT-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]-6-[2-(trifluoromethyl)piperidin-1-yl]-1H-pyridin-4-one Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)O)N1C(CCCC1)C(F)(F)F ZDEHFOOMMKTWNT-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- BICIVICGRFNJIG-UHFFFAOYSA-N 2-methoxy-n-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]acetamide Chemical compound C1=NC(NC(=O)COC)=CC(B2OC(C)(C)C(C)(C)O2)=C1 BICIVICGRFNJIG-UHFFFAOYSA-N 0.000 description 2
- RURWVXKSHIHATD-UHFFFAOYSA-N 4-[2-[(2-methylpropan-2-yl)oxy]-6-[2-(trifluoromethyl)piperidin-1-yl]pyridin-4-yl]pyridin-2-amine Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)N)N1C(CCCC1)C(F)(F)F RURWVXKSHIHATD-UHFFFAOYSA-N 0.000 description 2
- XEMQMFGMTHNQKA-UHFFFAOYSA-N 4-[6-[(2-methylpropan-2-yl)oxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]-3-(trifluoromethyl)morpholine Chemical compound C(C)(C)(C)OC1=CC(=CC(=N1)N1C(COCC1)C(F)(F)F)B1OC(C(O1)(C)C)(C)C XEMQMFGMTHNQKA-UHFFFAOYSA-N 0.000 description 2
- BFJHZUDHXKXYSL-UHFFFAOYSA-N 4-chloro-6-(2-chlorophenyl)-1H-pyridin-2-one Chemical compound ClC1=CC(NC(=C1)C1=C(C=CC=C1)Cl)=O BFJHZUDHXKXYSL-UHFFFAOYSA-N 0.000 description 2
- OITUCUIKXOUXJM-UHFFFAOYSA-N 4-chloro-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-2-one Chemical compound ClC1=CC(NC(=C1)C1=C(C=CC=C1)C(F)(F)F)=O OITUCUIKXOUXJM-UHFFFAOYSA-N 0.000 description 2
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- ZKTKXNKJTJUTCH-UHFFFAOYSA-N 6-(2-chlorophenyl)-4-hydroxy-1H-pyridin-2-one Chemical compound ClC1=C(C=CC=C1)C1=CC(=CC(N1)=O)O ZKTKXNKJTJUTCH-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- BDFOZVKHHWGGCD-UHFFFAOYSA-N N-[4-(2,6-dichloropyridin-4-yl)pyridin-2-yl]acetamide Chemical compound ClC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)Cl BDFOZVKHHWGGCD-UHFFFAOYSA-N 0.000 description 2
- WDUMAEVCZWQJJC-UHFFFAOYSA-N N-[4-(2-chloro-6-phenylmethoxypyridin-4-yl)pyridin-2-yl]acetamide Chemical compound C(C1=CC=CC=C1)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)Cl WDUMAEVCZWQJJC-UHFFFAOYSA-N 0.000 description 2
- SGKQJLXMAKMCIN-UHFFFAOYSA-N N-[4-(2-phenylmethoxy-6-pyridin-3-ylpyridin-4-yl)pyridin-2-yl]acetamide Chemical compound C(C1=CC=CC=C1)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C=1C=NC=CC=1 SGKQJLXMAKMCIN-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- JNSBEPKGFVENFS-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(F)(F)F JNSBEPKGFVENFS-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000004908 autophagic flux Effects 0.000 description 2
- 210000004957 autophagosome Anatomy 0.000 description 2
- XDHNQDDQEHDUTM-JQWOJBOSSA-N bafilomycin A1 Chemical compound CO[C@H]1\C=C\C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(OC)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C1 XDHNQDDQEHDUTM-JQWOJBOSSA-N 0.000 description 2
- XDHNQDDQEHDUTM-ZGOPVUMHSA-N bafilomycin A1 Natural products CO[C@H]1C=CC=C(C)C[C@H](C)[C@H](O)[C@H](C)C=C(C)C=C(OC)C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C1 XDHNQDDQEHDUTM-ZGOPVUMHSA-N 0.000 description 2
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000007932 molded tablet Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- NKPQBYDPUMQFCV-UHFFFAOYSA-N n-(4-chloropyridin-2-yl)-2-methoxyacetamide Chemical compound COCC(=O)NC1=CC(Cl)=CC=N1 NKPQBYDPUMQFCV-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- TWKMYNQPIICYNV-UHFFFAOYSA-N (2-methylpyridin-3-yl)boronic acid Chemical compound CC1=NC=CC=C1B(O)O TWKMYNQPIICYNV-UHFFFAOYSA-N 0.000 description 1
- ASXFMIDIRZPCGK-UHFFFAOYSA-N (4-methylpyridin-3-yl)boronic acid Chemical compound CC1=CC=NC=C1B(O)O ASXFMIDIRZPCGK-UHFFFAOYSA-N 0.000 description 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KXZYKTRZKJGUOX-UHFFFAOYSA-N 1,1-dimethyl-3-[4-[2-[(2-methylpropan-2-yl)oxy]-6-[2-(trifluoromethyl)phenyl]pyridin-4-yl]pyridin-2-yl]urea Chemical compound CN(C)C(=O)Nc1cc(ccn1)-c1cc(OC(C)(C)C)nc(c1)-c1ccccc1C(F)(F)F KXZYKTRZKJGUOX-UHFFFAOYSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- VYCIHDBIKGRENI-UHFFFAOYSA-N 1,3-bis[2,6-di(propan-2-yl)phenyl]-2h-imidazol-1-ium-2-ide Chemical group CC(C)C1=CC=CC(C(C)C)=C1N1C=CN(C=2C(=CC=CC=2C(C)C)C(C)C)[C]1 VYCIHDBIKGRENI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- FJNNGKMAGDPVIU-UHFFFAOYSA-N 2,4,6-trichloropyridine Chemical compound ClC1=CC(Cl)=NC(Cl)=C1 FJNNGKMAGDPVIU-UHFFFAOYSA-N 0.000 description 1
- HNOUFMDKCUFCLI-UHFFFAOYSA-N 2,4-dichloro-6-[2-(trifluoromethyl)phenyl]pyridine Chemical compound ClC1=NC(=CC(=C1)Cl)C1=C(C=CC=C1)C(F)(F)F HNOUFMDKCUFCLI-UHFFFAOYSA-N 0.000 description 1
- ZPGUMFCNPREQSF-UHFFFAOYSA-N 2-(2-methoxypropan-2-yl)pyrrolidine Chemical compound COC(C)(C)C1CCCN1 ZPGUMFCNPREQSF-UHFFFAOYSA-N 0.000 description 1
- YNEJOOCZWXGXDU-UHFFFAOYSA-N 2-(trifluoromethyl)piperazine Chemical compound FC(F)(F)C1CNCCN1 YNEJOOCZWXGXDU-UHFFFAOYSA-N 0.000 description 1
- RGGAMVFSNGDOSU-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]-4-phenylmethoxy-6-[2-(trifluoromethyl)phenyl]pyridine Chemical compound C(C1=CC=CC=C1)OC1=CC(=NC(=C1)C1=C(C=CC=C1)C(F)(F)F)OC(C)(C)C RGGAMVFSNGDOSU-UHFFFAOYSA-N 0.000 description 1
- LCLMQEHFVRCXJE-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-4-one Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)O)C1=C(C=CC=C1)C(F)(F)F LCLMQEHFVRCXJE-UHFFFAOYSA-N 0.000 description 1
- JXDHKPIKGVRNDF-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]-6-[3-(trifluoromethyl)morpholin-4-yl]-1H-pyridin-4-one Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)O)N1C(COCC1)C(F)(F)F JXDHKPIKGVRNDF-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- DHEKQQQJVFKLHN-UHFFFAOYSA-N 2-chloro-4-iodo-6-[(2-methylpropan-2-yl)oxy]pyridine Chemical compound CC(C)(C)OC1=CC(I)=CC(Cl)=N1 DHEKQQQJVFKLHN-UHFFFAOYSA-N 0.000 description 1
- NHWQMJMIYICNBP-UHFFFAOYSA-N 2-chlorobenzonitrile Chemical compound ClC1=CC=CC=C1C#N NHWQMJMIYICNBP-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HBCUPHWFUKNGIX-UHFFFAOYSA-N 3-(4-chloropyridin-2-yl)-1,1-dimethylurea Chemical compound CN(C(=O)NC1=NC=CC(=C1)Cl)C HBCUPHWFUKNGIX-UHFFFAOYSA-N 0.000 description 1
- QLADYDPROMQLCA-UHFFFAOYSA-N 3-(trifluoromethyl)morpholine Chemical compound FC(F)(F)C1COCCN1 QLADYDPROMQLCA-UHFFFAOYSA-N 0.000 description 1
- KLFPQNHKRHERBF-UHFFFAOYSA-N 3-cyclopropylmorpholine Chemical compound C1CC1C1NCCOC1 KLFPQNHKRHERBF-UHFFFAOYSA-N 0.000 description 1
- DCYKWKYBNWRLLZ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC(N)=C1 DCYKWKYBNWRLLZ-UHFFFAOYSA-N 0.000 description 1
- PWQWJZGRYFTIMR-UHFFFAOYSA-N 4-[6-[(2-methylpropan-2-yl)oxy]-4-phenylmethoxypyridin-2-yl]-3-(trifluoromethyl)morpholine Chemical compound C(C1=CC=CC=C1)OC1=CC(=NC(=C1)OC(C)(C)C)N1C(COCC1)C(F)(F)F PWQWJZGRYFTIMR-UHFFFAOYSA-N 0.000 description 1
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 1
- IQTHEAQKKVAXGV-UHFFFAOYSA-N 4-ditert-butylphosphanyl-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 IQTHEAQKKVAXGV-UHFFFAOYSA-N 0.000 description 1
- QIYHAMRKNNLROE-UHFFFAOYSA-N 4-hydroxy-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-2-one Chemical compound OC1=CC(NC(=C1)C1=C(C=CC=C1)C(F)(F)F)=O QIYHAMRKNNLROE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- IEOOBKBMGYVXQP-UHFFFAOYSA-N C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC=NC=C1)N1C(CCCC1)C(F)(F)F Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC=NC=C1)N1C(CCCC1)C(F)(F)F IEOOBKBMGYVXQP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000007493 Class III Phosphatidylinositol 3-Kinases Human genes 0.000 description 1
- 108010085715 Class III Phosphatidylinositol 3-Kinases Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- JCBKBBZSQCXGQP-UHFFFAOYSA-N N-[4-[2-(3-cyclopropylmorpholin-4-yl)-6-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)N1C(COCC1)C1CC1 JCBKBBZSQCXGQP-UHFFFAOYSA-N 0.000 description 1
- BFZHMHXBHTUCBS-UHFFFAOYSA-N N-[4-[2-[(2-methylpropan-2-yl)oxy]-6-(2-methylpyridin-3-yl)pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound CC(=O)Nc1cc(ccn1)-c1cc(OC(C)(C)C)nc(c1)-c1cccnc1C BFZHMHXBHTUCBS-UHFFFAOYSA-N 0.000 description 1
- ZWFOETQNVOHXIF-UHFFFAOYSA-N N-[4-[2-[(2-methylpropan-2-yl)oxy]-6-(4-methylpyridin-3-yl)pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound CC(=O)Nc1cc(ccn1)-c1cc(OC(C)(C)C)nc(c1)-c1cnccc1C ZWFOETQNVOHXIF-UHFFFAOYSA-N 0.000 description 1
- BQSZWFQMMHHVNZ-UHFFFAOYSA-N N-[4-[2-[(2-methylpropan-2-yl)oxy]-6-[2-(trifluoromethyl)phenyl]pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C1=C(C=CC=C1)C(F)(F)F BQSZWFQMMHHVNZ-UHFFFAOYSA-N 0.000 description 1
- NCSMBGDLKIXSKM-UHFFFAOYSA-N N-[4-[2-[(2-methylpropan-2-yl)oxy]-6-[2-(trifluoromethyl)pyridin-3-yl]pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C=1C(=NC=CC=1)C(F)(F)F NCSMBGDLKIXSKM-UHFFFAOYSA-N 0.000 description 1
- KLYXGCMKWCFOKP-UHFFFAOYSA-N N-[4-[2-[(2-methylpropan-2-yl)oxy]-6-[4-(trifluoromethyl)thiophen-3-yl]pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C1=CSC=C1C(F)(F)F KLYXGCMKWCFOKP-UHFFFAOYSA-N 0.000 description 1
- WHXKKNQUEYXKNJ-UHFFFAOYSA-N N-[4-[2-[1-ethyl-3-(trifluoromethyl)pyrazol-4-yl]-6-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C=1C(=NN(C=1)CC)C(F)(F)F WHXKKNQUEYXKNJ-UHFFFAOYSA-N 0.000 description 1
- MYFDQEJYVSJSBT-UHFFFAOYSA-N N-[4-[2-[2-(2-methoxypropan-2-yl)pyrrolidin-1-yl]-6-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)N1C(CCC1)C(C)(C)OC MYFDQEJYVSJSBT-UHFFFAOYSA-N 0.000 description 1
- INFZHDULEVDHQO-UHFFFAOYSA-N N-[4-[2-[4-ethylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-6-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)N1C(CN(CC1)S(=O)(=O)CC)C(F)(F)F INFZHDULEVDHQO-UHFFFAOYSA-N 0.000 description 1
- QFKLIPYSMUKMII-UHFFFAOYSA-N N-[4-[3-chloro-5-[(2-methylpropan-2-yl)oxy]phenyl]pyridin-2-yl]acetamide Chemical compound C(C)(C)(C)OC=1C=C(C=C(C=1)Cl)C1=CC(=NC=C1)NC(C)=O QFKLIPYSMUKMII-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- LWVQATYLVQPFDR-UHFFFAOYSA-N [4-(trifluoromethyl)thiophen-3-yl]boronic acid Chemical compound OB(O)c1cscc1C(F)(F)F LWVQATYLVQPFDR-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000006425 chlorocyclopropyl group Chemical group 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000002952 image-based readout Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000012855 insulin receptor internalization Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- JCTVEZRORUFSBC-UHFFFAOYSA-N methyl N-[4-[2-(2-chlorophenyl)-6-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(OC)=O)C1=C(C=CC=C1)Cl JCTVEZRORUFSBC-UHFFFAOYSA-N 0.000 description 1
- JTXYEYDNPZCWMW-UHFFFAOYSA-N methyl N-[4-[2-[(2-methylpropan-2-yl)oxy]-6-[2-(trifluoromethyl)phenyl]pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(OC)=O)C1=C(C=CC=C1)C(F)(F)F JTXYEYDNPZCWMW-UHFFFAOYSA-N 0.000 description 1
- JBSOUCCCKXBCEU-UHFFFAOYSA-N methyl N-[4-[2-[(2-methylpropan-2-yl)oxy]-6-[2-(trifluoromethyl)piperidin-1-yl]pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(OC)=O)N1C(CCCC1)C(F)(F)F JBSOUCCCKXBCEU-UHFFFAOYSA-N 0.000 description 1
- BGGULSZMJCFGCQ-UHFFFAOYSA-N methyl N-[4-[2-[(2-methylpropan-2-yl)oxy]-6-[2-(trifluoromethyl)pyridin-3-yl]pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(OC)=O)C=1C(=NC=CC=1)C(F)(F)F BGGULSZMJCFGCQ-UHFFFAOYSA-N 0.000 description 1
- ZKCBIDVWKFKDBS-UHFFFAOYSA-N methyl N-[4-[2-[1-ethyl-3-(trifluoromethyl)pyrazol-4-yl]-6-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C(C)(C)(C)OC1=NC(=CC(=C1)C1=CC(=NC=C1)NC(OC)=O)C=1C(=NN(C=1)CC)C(F)(F)F ZKCBIDVWKFKDBS-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- KZEFCECVTCHENL-UHFFFAOYSA-N methyl n-(4-chloropyridin-2-yl)carbamate Chemical compound COC(=O)NC1=CC(Cl)=CC=N1 KZEFCECVTCHENL-UHFFFAOYSA-N 0.000 description 1
- ZPELTWPNGKKNPZ-UHFFFAOYSA-N methyl n-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]carbamate Chemical compound C1=NC(NC(=O)OC)=CC(B2OC(C)(C)C(C)(C)O2)=C1 ZPELTWPNGKKNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000034778 micropinocytosis Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- WIPAEYIAUBBKRC-UHFFFAOYSA-N n-(4-chloropyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC(Cl)=CC=N1 WIPAEYIAUBBKRC-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229930004090 phosphatidylinositide Natural products 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical group CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
Description
Xは、C=Oまたは結合であり;
R1は、H、C1~C3アルキル、C1~C3ハロアルキル、C1~C3アルコキシC1~C3アルキル、C3~C6シクロアルキル、C3~C6シクロハロアルキル、C1~C3アルコキシ、C1~C3ハロアルコキシ、C3~C6シクロアルコキシメチル、N-C1~C3アルキルアミノ、N,N-ジC1~C3アルキルアミノ、1-ピロリジニル、1-ピペリジニルおよび1-アゼチジニルから選択され、但し、R1がC1~C3アルコキシ、C1~C3ハロアルコキシ、N-C1~C3アルキルアミノ、N,N-ジC1~C3アルキルアミノ、1-ピロリジニル、1-ピペリジニルまたは1-アゼチジニルである場合、XはC=Oであり;
R2は、水素、C1~C3ハロアルキルおよびC1~C3アルキルから選択され;
R3は、A、フェニルおよび単環式ヘテロアリールから選択され、前記フェニルおよび前記ヘテロアリールは任意で1つ以上のR4、R5、R6およびR7により置換されていてもよく;
R4、R5、R6およびR7は、独立して、ハロ、C1~C6アルキル、C3~C6シクロアルキル、C1~C6アルコキシ、C1~C3ハロアルコキシ、N,N-ジC1~C3アルキルアミノ、N-C1~C3アルキルアミノ、1-アゼチジニル、C1~C6ハロアルキル、アミノ、NHSO2R8、SO2R9およびヒドロキシから選択され;
R8は、C1~C3ハロアルキルまたはC1~C3アルキルであり;
R9は、R10、C1~C6アルキル、アミノ、N-C1~C3アルキルアミノ、N,N-ジC1~C3アルキルアミノおよびC1~C3アルコキシC1~C3アルキルから選択され、前記C1~C6アルキルおよび前記C1~C3アルコキシC1~C3アルキルは任意で1つのR10および/または1つ以上のハロにより置換されていてもよく;
R10は、各々任意で1つ以上のR11により置換されていてもよいフェニル、単環式ヘテロアリール、C3~C6シクロアルキル、ヘテロシクリルから選択され;
R11は、ハロ、C1~C3アルコキシC1~C3アルキル、アミノ、N-C1~C3アルキルアミノ、N,N-ジC1~C3アルキルアミノ、C1~C3ハロアルコキシ、C1~C3アルコキシ、C3~C6シクロアルキル、C1~C3ハロアルキルおよびC1~C3アルキルから選択され;
Aは、
R12は、水素、ハロ、COR13、C1~C6アルキル、C1~C3アルコキシC1~C3アルキル、C1~C6アルコキシ、C3~C6シクロアルキル、C1~C3シアノアルキル、C1~C3ハロアルキルから選択され;
R13は、C1~C3アルコキシ、N-C1~C3アルキルアミノ、N,N-ジC1~C3アルキルアミノ、1-ピロリジニル、1-ピペリジニルおよび1-アゼチジニルから選択され;
Yは、CH2、S、SO、SO2、NR14、NCOR9、NCOOR15、NSO2R9、NCOCH2R9、O、または結合であり;
R14は、H、C1~C3ハロアルキル、C1~C3アルコキシC1~C3アルキル、C1~C3アルキル、C3~C6シクロアルキルから選択され;
R15は、R10、C1~C6アルキルおよびC1~C3アルコキシC1~C3アルキルから選択され、前記C1~C6アルキルおよび前記C1~C3アルコキシC1~C3アルキルは任意で1つのR10および/または1つ以上のハロにより置換されていてもよい
化合物、またはその薬剤的に許容可能な塩を提供する。
本発明の本形態の1つの態様によれば、R3は、
Yは、CH2、Oおよび結合から選択され;
R4は、CF3、クロロ、シクロプロピルおよびメチルから選択され;
R5は、フルオロであり;ならびに
R12は、水素、シクロプロピル、メチル、1-メトキシ-1-メチル-エチルおよびCF3から選択される。
Yは、CH2、Oおよび結合から選択され;
R4は、CF3、クロロ、シクロプロピルおよびメチルから選択され;
R5は、フルオロであり;および
R12は、水素、シクロプロピル、メチルおよびCF3から選択される。
Yは、CH2およびOから選択され;
R4は、CF3、クロロシクロプロピルおよびクロロから選択され;
R5は、フルオロであり;ならびに
R12は、CF3およびシクロプロピルから選択される。
R1は、H、メチル、メトキシ、メトキシメチル、N,N-ジメチルアミノ、1-ピロリジニルおよびシクロプロピルから選択され;
R2は、水素であり;ならびに
R3は、
R1は、H、メチル、メトキシ、メトキシメチル、N,N-ジメチルアミノ、1-ピロリジニルおよびシクロプロピルから選択され;
R2は、水素であり;ならびに
R3は、
R1は、H、メチル、メトキシメチル、N,N-ジメチルアミノ、1-ピロリジニルおよびシクロプロピルから選択され;
R2は、水素であり;ならびに
R3は、
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
4-(2-アミノ-4-ピリジル)-6-(3-ピリジル)-1H-ピリジン-2-オン;
4-(2-アミノ-4-ピリジル)-6-(2-クロロフェニル)-1H-ピリジン-2-オン;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]-2-メトキシ-アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]シクロプロパンカルボキサミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(4-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(3-シクロプロピルモルホリン-4-イル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(2-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[4-(トリフルオロメチル)-3-チエニル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
1,1-ジメチル-3-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]ウレア;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]ピロリジン-1-カルボキサミド;または
N-[4-[2-[2-(1-メトキシ-1-メチル-エチル)ピロリジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
である。
4-(2-アミノ-4-ピリジル)-6-(3-ピリジル)-1H-ピリジン-2-オン;
4-(2-アミノ-4-ピリジル)-6-(2-クロロフェニル)-1H-ピリジン-2-オン;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]-2-メトキシ-アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]シクロプロパンカルボキサミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(4-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(4-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(3-シクロプロピルモルホリン-4-イル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(3-シクロプロピルモルホリン-4-イル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
3-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]-1,1-ジメチル-ウレア;または
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]ピロリジン-1-カルボキサミド
である。
本発明の本形態の1つの態様によれば、前記化合物は、
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
4-(2-アミノ-4-ピリジル)-6-(3-ピリジル)-1H-ピリジン-2-オン;
4-(2-アミノ-4-ピリジル)-6-(2-クロロフェニル)-1H-ピリジン-2-オン;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]-2-メトキシ-アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]シクロプロパンカルボキサミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(4-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(3-シクロプロピルモルホリン-4-イル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;または
N-[4-[2-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
である。
(1)薬物単独の投与と比較して、腫瘍増殖低下のより良好な有効性を得るかまたは腫瘍を排除さえすること、
(2)投与された化学療法薬のより少ない量の投与を提供すること、
(3)単剤化学療法薬および特定の他の組み合わされた療法で観察されるより、有害でない薬理的合併症を有する患者において耐容性良好である化学療法治療を提供すること、
(4)哺乳類、特にヒトにおいて種々のがん型のより広範囲の治療を提供すること、
(5)治療された患者の中でより高い奏効率を提供すること、
(6)標準的化学療法治療と比較して、治療された患者の中でより長い生存期間を提供すること、
(7)腫瘍進行までの時間を延長すること、および/または
(8)他のがん薬物の組合せが拮抗作用する公知の実例と比較して、単独で使用される薬物と少なくとも同様に良好な有効性および耐容性結果を得ること、
に役立つだろう。
本発明における化合物を、下記方法によって遊離塩基またはその薬剤的に許容可能な塩として製造することができる。かかる方法の以下の説明全体を通して、必要に応じて、有機合成の当業者により容易に理解されるように、適切な保護基を様々な反応物および中間体に付加し、その後除去するだろう。かかる保護基ならびに適切な保護基の例を使用するための従来方法は、例えば、Protective Groups in Organic Synthesis by T.W.Greene,P.G.M Wutz,4th Edition,Wiley-Interscience,New York,2006に記載されている。マイクロ波を、反応混合物の加熱の代わりに使用することができることは理解される。
(i)対応する式(I)の化合物の生成
式(I)の化合物を、例えば、式中、RXはF、OCH3、OC(CH3)3、またはOSiR’R’’R’’’(式中、R’、R’’およびR’’’は独立してアリール(フェニルなど)またはアルキル(メチルまたはtert-ブチルなど)である)であり得る、式(II)の化合物から出発することによって得ることができる。RXがFである場合、HCl水溶液を使用して例えば酸性加水分解によって(I)へ転化することができる。RXがOCH3である場合、例えば、クロロホルムなどの適切な溶媒中ヨウ化トリメチルシリルとの反応によって、または酢酸などの適切な溶媒中HBrとの反応によって、またはジクロロメタンなどの適切な溶媒中BBr3との反応によって(I)へ転化することができる。RXがOC(CH3)3である場合、例えば、ジクロロメタンなどの適切な溶媒中トリフルオロ酢酸との反応によって(I)へ転化することができる。RXがOSiR’R’’R’’’である場合、例えば、メタノールなどの適切な溶媒中HClによって、またはテトラヒドロフラン中フッ化テトラブチルアンモニウムの使用によって(I)へ転化することができる。この反応において鏡像異性的に純粋または豊富な化合物(II)を使用する場合、鏡像異性的に純粋または豊富な化合物(I)を得る。
使用される全溶媒は分析用グレードであり、市販無水溶媒を反応用に常に使用した。出発物質は商業的供給源から入手するか、または文献の方法に従って製造した。室温は+20~25℃を表す。溶媒混合物組成は、体積パーセンテージまたは体積比で表す。
Amphos (4-(N,N-ジメチルアミノ)フェニル)ジ-tert-ブチルホスフィン
anh. 無水
aq. 水性
BuLi ブチルリチウム
DCM ジクロロメタン
DMAc N,N-ジメチルアセトアミド
DME 1,2-ジメトキシエタン
DMF N,N-ジメチルホルムアミド
DMSO ジメチルスルホキシド
EtOAc 酢酸エチル
EtOH エタノール
h 時間
HPLC 高圧(または高速)液体クロマトグラフィー
KOtBu カリウムtert-ブトキシド
LCMS 液体クロマトグラフィー質量分析
MeCN アセトニトリル
2-MeTHF 2-メチルテトラヒドロフラン
MeOH メタノール
min. 分
NMR 各磁気共鳴
PEPPSI-iPr [1,3-ビス(2,6-ジイソプロピルフェニル)イミダゾール-2-イリデン](3-クロロピリジル)パラジウム(II)ジクロリド
Pd(OAc)2 酢酸パラジウム(II)
PdCl2(dppf) [1,1’-ビス(ジフェニルホスフィノ)フェロセン]ジクロロパラジウム(II)
quant. 定量的
rt 室温
sat. 飽和
S-Phos 2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル
TFA トリフルオロ酢酸
THF テトラヒドロフラン
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-(2,6-ジクロロ-4-ピリジル)-2-ピリジル]アセトアミド
N-[4-(2-ベンジルオキシ-6-クロロ-4-ピリジル)-2-ピリジル]アセトアミド
N-[4-(2-ベンジルオキシ-6-(3-ピリジル)-4-ピリジル)-2-ピリジル]アセトアミド
4-(2-アミノ-4-ピリジル)-6-(3-ピリジル)-1H-ピリジン-2-オン
6-(2-クロロフェニル)-4-ヒドロキシ-1H-ピリジン-2-オン
2,4-ジクロロ-6-(2-クロロフェニル)ピリジン
4-クロロ-6-(2-クロロフェニル)-1H-ピリジン-2-オン
N-(4-クロロ-2-ピリジル)-2-メトキシ-アセトアミド
2-メトキシ-N-[4-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)-2-ピリジル]アセトアミド
4-(2-アミノ-4-ピリジル)-6-(2-クロロフェニル)-1H-ピリジン-2-オンおよびN-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]-2-メトキシ-アセトアミド
4-ベンジルオキシ-2,6-ジクロロ-ピリジン
4-ベンジルオキシ-2-tert-ブトキシ-6-クロロ-ピリジン
4-ベンジルオキシ-2-tert-ブトキシ-6-[2-(トリフルオロメチル)-1-ピペリジル]ピリジン
2-tert-ブトキシ-6-[2-(トリフルオロメチル)-1-ピペリジル]ピリジン-4-オール
トリフルオロメタンスルホン酸[2-tert-ブトキシ-6-[2-(トリフルオロメチル)-1-ピペリジル]-4-ピリジル]
2-tert-ブトキシ-4-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)-6-[2-(トリフルオロメチル)-1-ピペリジル]ピリジン
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
4-[2-tert-ブトキシ-6-[2-(トリフルオロメチル)-1-ピペリジル]-4-ピリジル]ピリジン-2-アミン
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]シクロプロパンカルボキサミド
4-(4-ベンジルオキシ-6-tert-ブトキシ-2-ピリジル)-3-(トリフルオロメチル)モルホリン
2-tert-ブトキシ-6-[3-(トリフルオロメチル)モルホリン-4-イル]ピリジン-4-オール
トリフルオロメタンスルホン酸[2-tert-ブトキシ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-4-ピリジル]
4-[6-tert-ブトキシ-4-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)-2-ピリジル]-3-(トリフルオロメチル)モルホリン
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-(2-tert-ブトキシ-6-クロロ-4-ピリジル)-2-ピリジル]アセトアミド
1-エチルスルホニル-3-(トリフルオロメチル)ピペラジン
N-[4-[2-tert-ブトキシ-6-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-4-ピリジル]-2-ピリジル]アセトアミド
N-[4-[2-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-[2-tert-ブトキシ-6-(3-シクロプロピルモルホリン-4-イル)-4-ピリジル]-2-ピリジル]アセトアミド
N-[4-[2-(3-シクロプロピルモルホリン-4-イル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-[2-tert-ブトキシ-6-[2-(トリフルオロメチル)フェニル]-4-ピリジル]-2-ピリジル]アセトアミド
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-[2-tert-ブトキシ-6-[2-(トリフルオロメチル)-3-ピリジル]-4-ピリジル]-2-ピリジル]アセトアミド
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-[2-tert-ブトキシ-6-(2-メチル-3-ピリジル)-4-ピリジル]-2-ピリジル]アセトアミド
N-[4-[2-(2-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-[2-tert-ブトキシ-6-(4-メチル-3-ピリジル)-4-ピリジル]-2-ピリジル]アセトアミド
N-[4-[2-(4-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-[2-tert-ブトキシ-6-[4-(トリフルオロメチル)-3-チエニル]-4-ピリジル]-2-ピリジル]アセトアミド
N-[4-[2-オキソ-6-[4-(トリフルオロメチル)-3-チエニル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-[2-tert-ブトキシ-6-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-4-ピリジル]-2-ピリジル]アセトアミド
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル
N-[4-(2-tert-ブトキシ-6-クロロ-4-ピリジル)-2-ピリジル]カルバミン酸メチル
N-[4-[2-tert-ブトキシ-6-[2-(トリフルオロメチル)フェニル]-4-ピリジル]-2-ピリジル]カルバミン酸メチル
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル
N-[4-[2-tert-ブトキシ-6-(2-クロロフェニル)-4-ピリジル]-2-ピリジル]カルバミン酸メチル
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル
N-[4-[2-tert-ブトキシ-6-[2-(トリフルオロメチル)-3-ピリジル]-4-ピリジル]-2-ピリジル]カルバミン酸メチル
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル
N-[4-[2-tert-ブトキシ-6-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-4-ピリジル]-2-ピリジル]カルバミン酸メチル
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル
4-ベンジルオキシ-2-tert-ブトキシ-6-[2-(トリフルオロメチル)フェニル]ピリジン
2-tert-ブトキシ-6-[2-(トリフルオロメチル)フェニル]ピリジン-4-オール
トリフルオロメタンスルホン酸[2-tert-ブトキシ-6-[2-(トリフルオロメチル)フェニル]-4-ピリジル]
2-tert-ブトキシ-4-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)-6-[2-(トリフルオロメチル)フェニル]ピリジン
N-(4-クロロ-2-ピリジル)-N-フェノキシカルボニル-カルバミン酸フェニル
3-(4-クロロ-2-ピリジル)-1,1-ジメチル-ウレア
3-[4-[2-tert-ブトキシ-6-[2-(トリフルオロメチル)フェニル]-4-ピリジル]-2-ピリジル]-1,1-ジメチル-ウレア
1,1-ジメチル-3-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]ウレア
4-ヒドロキシ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-2-オン
2,4-ジクロロ-6-[2-(トリフルオロメチル)フェニル]ピリジン
4-クロロ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-2-オン
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]ピロリジン-1-カルボキサミド
N-[4-[2-tert-ブトキシ-6-[2-(1-メトキシ-1-メチル-エチル)ピロリジン-1-イル]-4-ピリジル]-2-ピリジル]アセトアミド
N-[4-[2-[2-(1-メトキシ-1-メチル-エチル)ピロリジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
N-[4-[2-tert-ブトキシ-6-[2-(トリフルオロメチル)-1-ピペリジル]-4-ピリジル]-2-ピリジル]カルバミン酸メチル
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル
Vps34生化学アッセイ
本発明の化合物の希釈系列を最終アッセイ濃度の100倍でDMSO中に調製した(n1=n0/3、10点)。化合物をアッセイ緩衝液(Life technologies 緩衝液Q、PV5125、2mM DTTおよび2mM MnCl2を含む5倍希釈)のアッセイ濃度の4倍までさらに希釈した。希釈された2.5μlの化合物を384ウェルアッセイプレートに添加し、次いで、16.5nM Vps34酵素(Life technologies、PV5126)2.5μlを添加した。酵素および化合物を室温で15分間プレインキュベートした。それから、アッセイ緩衝液中20μM ATP(Life technologies、PV3227)および200μM PI:PS基質(Life technologies、PV5122)を含有する5μlの基質ミックスを、化合物および酵素を含むウェルに添加した。数回のピペット操作によって混合を行った。反応物を室温で1時間インキュベートした。それから、TR-FRET緩衝液中、Adapta Eu抗ADP抗体(2.3nM)、Alexa Fluor 647 ADPトレーサー(9nM)およびEDTA(30mM)を含有する、Adaptaキナーゼアッセイキット使用説明書(Life technologies、PV5099)に記載されている通りに調製された5μlの停止検出ミックスを添加して反応をクエンチした。数回のピペット操作によって混合を行った。それから、アッセイを室温で30分間インキュベートし、Artemisマイクロプレートリーダーで読んだ。DMSO処理したコントロールサンプルと比較した化合物の阻害パーセントを算出した。Dotmaticsソフトウェアを使用することによって、阻害パーセントに対する化合物濃度をフィットしてIC50値を得た。
高含有量スクリーニングオートファジーアッセイ
LC3(GFP-LC3)タグされた緑色蛍光タンパク質(GFP)を安定に発現するヒト骨肉腫細胞(HOS)を使用して、独占所有権のある化合物のオートファジーに対する阻害効果を決定した。この目的のため、5nMバフィロマイシンA1(Sigma-Aldrich)の存在下、500nM mTOR阻害剤KU-0063794の使用によって、オートファジーを活性化した。直ちに、DMEM-高改変培地(Hi-Clone カタログ#SH30285.01)中透明底96ウェルプレート中に細胞を一夜入れた。実験の開始時、培地を取り出し、mTOR阻害剤、バフィロマイシンA1および媒体または指定の試験化合物を含有する新しい培地と入れ換えた。6時間後、培地を取り出し、細胞を氷冷リン酸緩衝生理食塩水(PBS)で2回洗浄し、室温で20分間、4%パラホルムアルデヒドで固定した。それから、細胞を氷冷PBSで2回洗浄した後、核染色を行うためにPBS中1μg/mlのHoechst33342を添加した。4℃で一夜インキュベートした後、細胞をPBSで1回洗浄して、過剰の染料を取り除き、100μlのPBSを各ウェルに添加した。ImageXpress自動顕微鏡(Molecular Devices Inc.)を使用して、ウェル当たり6画像、20倍の拡大倍率で画像を撮影して、MetaXpressソフトウェアを用いて解析してLC3-GFP病巣を特定した。細胞値当たりの病巣面積を使用して用量反応曲線を作成し、GraphPad Prismソフトウェアの非線形フィッティング解析を使用して、IC50値を算出した。
N-[4-[2-(4-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(3-シクロプロピルモルホリン-4-イル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
3-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]-1,1-ジメチル-ウレア;および
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]ピロリジン-1-カルボキサミド。
Claims (38)
- 式(I):
Xは、C=Oまたは結合であり;
R1は、H、C1~C3アルキル、C1~C3ハロアルキル、C1~C3アルコキシC1~C3アルキル、C3~C6シクロアルキル、C3~C6シクロハロアルキル、C1~C3アルコキシ、C1~C3ハロアルコキシ、C3~C6シクロアルコキシメチル、N-C1~C3アルキルアミノ、N,N-ジC1~C3アルキルアミノ、1-ピロリジニル、1-ピペリジニルおよび1-アゼチジニルから選択され、但し、R1がC1~C3アルコキシ、C1~C3ハロアルコキシ、N-C1~C3アルキルアミノ、N,N-ジC1~C3アルキルアミノ、1-ピロリジニル、1-ピペリジニルまたは1-アゼチジニルである場合、XはC=Oであり;
R2は、水素、C1~C3ハロアルキルおよびC1~C3アルキルから選択され;
R3は、A、フェニルおよび単環式ヘテロアリールから選択され、前記フェニルおよび前記ヘテロアリールは任意で1つ以上のR4、R5、R6およびR7により置換されていてもよく;
R4、R5、R6およびR7は、独立して、ハロ、C1~C6アルキル、C3~C6シクロアルキル、C1~C6アルコキシ、C1~C3ハロアルコキシ、N,N-ジC1~C3アルキルアミノ、N-C1~C3アルキルアミノ、1-アゼチジニル、C1~C6ハロアルキル、アミノ、NHSO2R8、SO2R9およびヒドロキシから選択され;
R8は、C1~C3ハロアルキルまたはC1~C3アルキルであり;
R9は、R10、C1~C6アルキル、アミノ、N-C1~C3アルキルアミノ、N,N-ジC1~C3アルキルアミノおよびC1~C3アルコキシC1~C3アルキルから選択され、前記C1~C6アルキルおよび前記C1~C3アルコキシC1~C3アルキルは任意で1つのR10および/または1つ以上のハロにより置換されていてもよく;
R10は、各々任意で1つ以上のR11により置換されていてもよいフェニル、単環式ヘテロアリール、C3~C6シクロアルキル、ヘテロシクリルから選択され;
R11は、ハロ、C1~C3アルコキシC1~C3アルキル、アミノ、N-C1~C3アルキルアミノ、N,N-ジC1~C3アルキルアミノ、C1~C3ハロアルコキシ、C1~C3アルコキシ、C3~C6シクロアルキル、C1~C3ハロアルキルおよびC1~C3アルキルから選択され;
Aは、
R12は、水素、ハロ、COR13、C1~C6アルキル、C1~C3アルコキシC1~C3アルキル、C1~C6アルコキシ、C3~C6シクロアルキル、C1~C3シアノアルキル、C1~C3ハロアルキルから選択され;
R13は、C1~C3アルコキシ、N-C1~C3アルキルアミノ、N,N-ジC1~C3アルキルアミノ、1-ピロリジニル、1-ピペリジニルおよび1-アゼチジニルから選択され;
Yは、CH2、S、SO、SO2、NR14、NCOR9、NCOOR15、NSO2R9、NCOCH2R9、O、または結合であり;
R14は、H、C1~C3ハロアルキル、C1~C3アルコキシC1~C3アルキル、C1~C3アルキル、C3~C6シクロアルキルから選択され;
R15は、R10、C1~C6アルキルおよびC1~C3アルコキシC1~C3アルキルから選択され、前記C1~C6アルキルおよび前記C1~C3アルコキシC1~C3アルキルは任意で1つのR10および/または1つ以上のハロにより置換されていてもよい、
の化合物、またはその薬剤的に許容可能な塩。 - R2は、水素またはC1~C3アルキルである、請求項1に記載の化合物;またはその薬剤的に許容可能な塩。
- R1は、H、C1~C3アルキル、C1~C3アルコキシ、C1~C3ハロアルコキシ、C1~C3アルコキシC1~C3アルキル、N,N-ジC1~C3アルキルアミノ、1-ピロリジニルおよびC3~C6シクロアルキルから選択される、請求項1または請求項2に記載の化合物、またはその薬剤的に許容可能な塩。
- R1は、H、メチル、メトキシ、メトキシメチル、N,N-ジメチルアミノ、1-ピロリジニルおよびシクロプロピルから選択される、請求項1~3のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩。
- R1は、H、メチル、メトキシメチル、N,N-ジメチルアミノ、1-ピロリジニルおよびシクロプロピルから選択される、請求項1~4のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩。
- R3は、A、フェニルならびにピリジル、チエニル、フリル、ピリミジニルおよびピラゾリルから選択される単環式ヘテロアリールから選択され、前記フェニルおよび前記ヘテロアリールは任意でR4および/またはR5により置換されていてもよい、請求項1~5のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩。
- R3は、A、フェニルならびにピリジルから選択され、前記フェニルならびに前記ピリジルは任意で独立してR4および/またはR5により置換されていてもよい、請求項1~6のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩。
- R4、R5、R6およびR7は、独立して、フルオロ、クロロ、C1~C3アルキル、C3~C6シクロアルキル、C1~C3フルオロアルキルおよびSO2R9から選択される、
請求項1~7のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩。 - Yは、CH2、NSO2R9、Oまたは結合である、請求項1~8のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩。
- Yは、CH2、Oまたは結合である、請求項1~9のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩。
- R12は、水素、C1~C3アルキル、C1~C3アルコキシC1~C3アルキル、C1~C3ハロアルキルおよびC3~C6シクロアルキルから選択される、請求項1~10のいずれか一項に記載の化合物;またはその薬剤的に許容可能な塩。
- R12は、水素、C1~C3アルキル、C1~C3ハロアルキルおよびC3~C6シクロアルキルから選択される、請求項1~11のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩。
- R9は、R10、N,N-ジC1~C3アルキルアミノおよびメトキシC1~C3アルキルから選択され、前記C1~C3アルキルは任意で1つのR10により置換されていてもよい、請求項1~12のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩。
- R10は、フェニル、ピリジル、イミダゾリル、イソオキサゾリル、オキサゾリル、シクロプロピル、シクロペンチル、ピロリジニル、テトラヒドロフリルから選択され、各々は任意で1つ以上のメチルおよび/またはフルオロにより置換されていてもよい、請求項1~13のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩。
- 前記化合物は、
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
4-(2-アミノ-4-ピリジル)-6-(3-ピリジル)-1H-ピリジン-2-オン;
4-(2-アミノ-4-ピリジル)-6-(2-クロロフェニル)-1H-ピリジン-2-オン;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]-2-メトキシ-アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]シクロプロパンカルボキサミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(4-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(3-シクロプロピルモルホリン-4-イル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(2-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[4-(トリフルオロメチル)-3-チエニル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
1,1-ジメチル-3-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]ウレア;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]ピロリジン-1-カルボキサミド;
N-[4-[2-[2-(1-メトキシ-1-メチル-エチル)ピロリジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
である、請求項1に記載の化合物、またはその薬剤的に許容可能な塩。 - 前記化合物は、
4-(2-アミノ-4-ピリジル)-6-(3-ピリジル)-1H-ピリジン-2-オン;
4-(2-アミノ-4-ピリジル)-6-(2-クロロフェニル)-1H-ピリジン-2-オン;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]-2-メトキシ-アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]シクロプロパンカルボキサミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(4-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(4-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(3-シクロプロピルモルホリン-4-イル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(3-シクロプロピルモルホリン-4-イル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
3-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]-1,1-ジメチル-ウレア;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]ピロリジン-1-カルボキサミド
である、請求項1に記載の化合物、またはその薬剤的に許容可能な塩。 - 前記化合物は、
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
4-(2-アミノ-4-ピリジル)-6-(3-ピリジル)-1H-ピリジン-2-オン;
4-(2-アミノ-4-ピリジル)-6-(2-クロロフェニル)-1H-ピリジン-2-オン;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]-2-メトキシ-アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]シクロプロパンカルボキサミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(2-クロロフェニル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)フェニル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-(4-メチル-3-ピリジル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-3-ピリジル]-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[1-エチル-3-(トリフルオロメチル)ピラゾール-4-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-オキソ-6-[3-(トリフルオロメチル)モルホリン-4-イル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-オキソ-6-[2-(トリフルオロメチル)-1-ピペリジル]-1H-ピリジン-4-イル]-2-ピリジル]カルバミン酸メチル;
N-[4-[2-(3-シクロプロピルモルホリン-4-イル)-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド;
N-[4-[2-[4-エチルスルホニル-2-(トリフルオロメチル)ピペラジン-1-イル]-6-オキソ-1H-ピリジン-4-イル]-2-ピリジル]アセトアミド
である、請求項1に記載の化合物、またはその薬剤的に許容可能な塩。 - 疾病を治療するための組成物であって、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩を含有する、組成物。
- がんを治療するための組成物であって、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩を含有する、組成物。
- がんを治療するための組成物であって、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩を含有し、前記がんは、トリプルネガティブ乳がんなどの乳がん、膀胱がん、肝がん、子宮頸がん、膵がん、白血病、リンパ腫、腎がん、結腸がん、グリオーマ、前立腺がん、卵巣がん、メラノーマ、および肺がんならびに酸素欠乏腫瘍からなる群から選択される、組成物。
- 酸素欠乏腫瘍を治療するための組成物であって、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩を含有する、組成物。
- がんを治療するための組成物であって、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩を含有し、前記がん治療は、放射線療法を更に含む、組成物。
- 2型糖尿病を治療するための組成物であって、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩を含有する、組成物。
- 疾病を治療するための組成物であって、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩を含有し、前記疾病は、炎症性疾患、自己免疫疾患、神経変性疾患、心血管障害およびウイルス感染からなる群から選択される、組成物。
- がん治療のための薬物の製造における、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩の使用。
- がんは、トリプルネガティブ乳がんなどの乳がん、膀胱がん、肝がん、子宮頸がん、膵がん、白血病、リンパ腫、腎がん、結腸がん、グリオーマ、前立腺がん、卵巣がん、メラノーマ、および肺がんならびに酸素欠乏腫瘍である、前記がん治療のための薬物の製造における、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩の使用。
- 酸素欠乏腫瘍の治療のための薬物の製造における、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩の使用。
- 2型糖尿病治療のための薬物の製造における、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩の使用。
- 炎症性疾患、自己免疫疾患、神経変性疾患、心血管障害およびウイルス感染から選択される、疾病の治療のための薬物の製造における、請求項1~24のいずれか一項に記載の化合物、またはその薬剤的に許容可能な塩の使用。
- 請求項1~24のいずれか一項に記載の化合物、もしくはその薬剤的に許容可能な塩、ならびに薬剤的に許容可能な希釈剤、担体および/または賦形剤を含む医薬組成物。
- 請求項1に記載の化合物、またはその薬剤的に許容可能な塩の治療有効量、ならびにアルキル化剤、代謝拮抗薬、抗がんカンプトテシン誘導体、植物由来抗がん薬、抗生物質、酵素、白金配位錯体、チロシンキナーゼ阻害薬、ホルモン、ホルモン拮抗薬、モノクローナル抗体、インターフェロン、および生物応答調節剤から選択される別の抗がん薬を含む医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022198540A JP2023021276A (ja) | 2017-08-23 | 2022-12-13 | ピリジルピリドン化合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17187544 | 2017-08-23 | ||
EP17187544.6 | 2017-08-23 | ||
PCT/EP2018/072788 WO2019038387A1 (en) | 2017-08-23 | 2018-08-23 | PYRIDYLPYRIDONE COMPOUNDS |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022198540A Division JP2023021276A (ja) | 2017-08-23 | 2022-12-13 | ピリジルピリドン化合物 |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2020531486A JP2020531486A (ja) | 2020-11-05 |
JP2020531486A5 JP2020531486A5 (ja) | 2021-09-30 |
JPWO2019038387A5 JPWO2019038387A5 (ja) | 2022-10-20 |
JP7199737B2 true JP7199737B2 (ja) | 2023-01-06 |
Family
ID=59686881
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020510096A Active JP7199737B2 (ja) | 2017-08-23 | 2018-08-23 | ピリジルピリドン化合物 |
JP2022198540A Pending JP2023021276A (ja) | 2017-08-23 | 2022-12-13 | ピリジルピリドン化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022198540A Pending JP2023021276A (ja) | 2017-08-23 | 2022-12-13 | ピリジルピリドン化合物 |
Country Status (19)
Country | Link |
---|---|
US (2) | US11219618B2 (ja) |
EP (2) | EP3672941B1 (ja) |
JP (2) | JP7199737B2 (ja) |
KR (1) | KR20200043413A (ja) |
CN (3) | CN116891431A (ja) |
AU (2) | AU2018320416B2 (ja) |
CA (1) | CA3072974A1 (ja) |
DK (1) | DK3672941T3 (ja) |
ES (1) | ES2910839T3 (ja) |
HR (1) | HRP20220571T1 (ja) |
HU (1) | HUE058977T2 (ja) |
IL (3) | IL302356A (ja) |
LT (1) | LT3672941T (ja) |
PL (1) | PL3672941T3 (ja) |
PT (1) | PT3672941T (ja) |
RS (1) | RS63161B1 (ja) |
SI (1) | SI3672941T1 (ja) |
TW (2) | TW202308996A (ja) |
WO (1) | WO2019038387A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112088157B (zh) | 2017-12-22 | 2023-12-26 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物 |
CN117083064A (zh) * | 2020-11-25 | 2023-11-17 | 德西费拉制药有限责任公司 | 作为vps34抑制剂用于治疗病毒感染的吡啶基吡啶酮衍生物 |
TW202320797A (zh) * | 2021-08-13 | 2023-06-01 | 美商迪賽孚爾製藥有限公司 | 使用vps34抑制劑之組合療法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
JP2017503813A (ja) | 2014-01-14 | 2017-02-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | ヘテロアリール及びそれらの使用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2485166A1 (en) * | 2002-05-21 | 2003-12-04 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds |
TW200908984A (en) * | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
CN103270026A (zh) * | 2010-12-21 | 2013-08-28 | 诺瓦提斯公司 | 作为vps34抑制剂的联-杂芳基化合物 |
US8815853B2 (en) | 2010-12-23 | 2014-08-26 | Sanofi | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof |
GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
CN104718201A (zh) * | 2012-06-12 | 2015-06-17 | 艾伯维公司 | 吡啶酮和哒嗪酮衍生物 |
FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
EP3094326A4 (en) | 2014-01-14 | 2017-07-26 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
HUE050863T2 (hu) * | 2016-02-19 | 2021-01-28 | Sprint Bioscience Ab | Rák és cukorbetegség kezelésére alkalmazható 6-aril-4-(morfolin-4-il)-1H-piridin-2-on vegyületek |
RS60900B1 (sr) | 2016-02-19 | 2020-11-30 | Sprint Bioscience Ab | Jedinjenja 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisna za lečenje kancera i dijabetesa |
-
2018
- 2018-08-23 ES ES18759308T patent/ES2910839T3/es active Active
- 2018-08-23 JP JP2020510096A patent/JP7199737B2/ja active Active
- 2018-08-23 TW TW111144233A patent/TW202308996A/zh unknown
- 2018-08-23 EP EP18759308.2A patent/EP3672941B1/en active Active
- 2018-08-23 KR KR1020207006936A patent/KR20200043413A/ko not_active Application Discontinuation
- 2018-08-23 CA CA3072974A patent/CA3072974A1/en active Pending
- 2018-08-23 US US16/639,895 patent/US11219618B2/en active Active
- 2018-08-23 LT LTEPPCT/EP2018/072788T patent/LT3672941T/lt unknown
- 2018-08-23 AU AU2018320416A patent/AU2018320416B2/en active Active
- 2018-08-23 IL IL302356A patent/IL302356A/en unknown
- 2018-08-23 PL PL18759308T patent/PL3672941T3/pl unknown
- 2018-08-23 CN CN202310818638.5A patent/CN116891431A/zh active Pending
- 2018-08-23 HR HRP20220571TT patent/HRP20220571T1/hr unknown
- 2018-08-23 CN CN201880059987.0A patent/CN111094244B/zh active Active
- 2018-08-23 RS RS20220398A patent/RS63161B1/sr unknown
- 2018-08-23 TW TW107129492A patent/TWI787335B/zh active
- 2018-08-23 HU HUE18759308A patent/HUE058977T2/hu unknown
- 2018-08-23 DK DK18759308.2T patent/DK3672941T3/da active
- 2018-08-23 PT PT187593082T patent/PT3672941T/pt unknown
- 2018-08-23 WO PCT/EP2018/072788 patent/WO2019038387A1/en unknown
- 2018-08-23 CN CN202310818724.6A patent/CN116903526A/zh active Pending
- 2018-08-23 SI SI201830631T patent/SI3672941T1/sl unknown
- 2018-08-23 EP EP22155562.6A patent/EP4056556A1/en active Pending
-
2020
- 2020-02-20 IL IL272805A patent/IL272805B/en unknown
-
2021
- 2021-12-15 US US17/644,486 patent/US20220218688A1/en active Pending
-
2022
- 2022-04-25 IL IL292485A patent/IL292485B2/en unknown
- 2022-12-13 JP JP2022198540A patent/JP2023021276A/ja active Pending
-
2023
- 2023-10-31 AU AU2023258375A patent/AU2023258375A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017503813A (ja) | 2014-01-14 | 2017-02-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | ヘテロアリール及びそれらの使用 |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7201260B2 (ja) | ピリジンアミン-ピリドンおよびピリミジンアミン-ピリドン化合物 | |
RU2754664C2 (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
JP2023021276A (ja) | ピリジルピリドン化合物 | |
JP2023021277A (ja) | アザインドリルピリドンおよびジアザインドリルピリドン化合物 | |
JP2023021268A (ja) | モルホリニルピリドン化合物 | |
RU2805334C2 (ru) | Пиридилпиридоны |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210820 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210820 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220712 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20221012 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221115 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221214 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7199737 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |